LSL Pharma Group Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '21 Jul 31, 2021
Cash & Equivalents	0.45	0.3	0.01	0.01	-
Cash & Short-Term Investments	0.45	0.3	0.01	0.01	-
Cash Growth	173.78%	3600.00%	-	-	-
Accounts Receivable	5.89	4.95	2.68	1.23	-
Other Receivables	-	-	-	-	0.02
Total Trade Receivables	5.89	4.95	2.68	1.23	0.02
Inventory	13.39	9.22	4.11	2.96	-
Other Current Assets	0.93	1.02	0.41	0.21	-
Total Current Assets	20.66	15.48	7.2	4.4	0.02
Net Property, Plant & Equipment	24.75	22.94	14.75	13.92	-
Other Intangible Assets	14.33	13.27	8.93	8.98	-
Goodwill	0.16	0.16	-	-	-
Other Long-Term Assets	0.3	1.77	0.02	0.02	-
Total Assets	60.19	53.61	30.9	27.31	0.02
Accounts Payable	4.12	5.3	5.98	6.12	0.09
Short-Term Debt	8.04	2.56	3.77	3.78	0.11
Current Portion of Long-Term Debt	0.9	1.45	5.22	1.58	-
Current Portion of Leases	0.48	0.45	0.12	0.14	-
Unearned Revenue	-	-	-	0.01	-
Total Current Liabilities	13.54	9.75	15.07	11.62	0.2
Long-Term Debt	15.43	12.75	4.73	7.84	-
Long-Term Leases	4.06	4.43	2.44	2.56	-
Other Long-Term Liabilities	1.79	1.79	-	-	-
Total Long-Term Liabilities	21.27	18.97	7.17	10.4	-
Total Liabilities	34.81	28.72	22.25	22.02	0.2
Common Stock	38.45	36.39	24.2	15.05	2.93
Additional Paid-in Capital	3.57	3.42	2.69	-	0.45
Retained Earnings	-16.64	-14.92	-18.23	-9.76	-3.56
Shareholders' Equity	25.38	24.89	8.66	5.29	-0.19
Total Liabilities & Equity	60.19	53.61	30.9	27.31	17.31
Total Debt	28.91	21.64	16.27	15.9	0.11
Net Cash (Debt)	-28.46	-21.34	-16.26	-15.89	-0.11
Net Cash Per Share	-	-0.20	-0.20	-	-
Book Value	25.38	24.89	8.66	5.29	-0.19
Book Value Per Share	-	0.24	0.11	-	-
Tangible Book Value	10.89	11.46	-0.28	-3.69	-0.19
Tangible Book Value Per Share	-	0.11	-0.00	-	-

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.